Drug Profile
Factor IX - Emisphere
Latest Information Update: 22 Dec 2021
Price :
$50
*
At a glance
- Originator Emisphere Technologies
- Class Antihaemorrhagics; Blood coagulation factors
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Haemophilia
Most Recent Events
- 08 Dec 2020 Emisphere Technologies has been acquired by Novo Nordisk
- 20 Feb 1997 New profile
- 20 Feb 1997 Suspended-Unspecified Phase in Haemophilia in USA (PO)